The Man Who Challenged Glioblastoma

The acclaimed Australian pathologist and co-director of the Melanoma Institute Australia underwent a world-first experimental brain tumour treatment of his own design — and, in doing so, may have changed the future of cancer medicine for generations to come.

By Our Science & Medicine Correspondent | Sunday, 7 June 2026

Professor Richard Scolyer, one of Australia’s most celebrated medical scientists, has died at the age of 59, three years after being diagnosed with glioblastoma — one of the most aggressive and lethal forms of brain cancer known to medicine. His passing marks the end of a life that was, in every measurable sense, extraordinary: a career defined by scientific breakthroughs that have saved countless lives, a personal courage that inspired a nation, and a final act of selfless contribution that may yet alter the course of oncology worldwide.

Scolyer’s diagnosis in 2023 would have broken many people. Instead, it galvanised him. Together with his close friend and colleague Professor Georgina Long, he chose not to accept the grim prognosis that accompanies glioblastoma — a tumour with a median survival of less than twelve months — and instead became the first person in the world to undergo a combination of pre-surgical immunotherapy drugs alongside a personalised tumour vaccine. The procedure drew on the very immunotherapy breakthroughs that Scolyer and Long had pioneered in treating advanced melanoma, adapted and applied, for the first time ever, to brain cancer.

A Career That Transformed Cancer Medicine

Richard Scolyer was born in Launceston, Tasmania, and rose to become one of Australia’s most internationally recognised pathologists. His most transformative contribution came through his long partnership with Professor Georgina Long at the Melanoma Institute Australia, where the two co-directors revolutionised the prognosis for patients diagnosed with advanced melanoma. When they began their work, fewer than one in ten patients could expect long-term survival. Today, approximately half of all advanced melanoma patients are considered essentially cured — one of the most dramatic reversals of fortune in modern oncology.

Their research established that immunotherapy is significantly more effective when administered as a combination of drugs, and crucially, when given before any surgical removal of a tumour. It was this very insight that would later inform the experimental protocol applied to Scolyer’s own glioblastoma. Beyond research, he was deeply committed to mentoring the next generation of pathologists, citing this as one of the greatest sources of pride in his career. In 2024, he and Long were jointly named Australian of the Year — an honour that felt not merely deserved, but long overdue.

The Experiment: Becoming His Own Patient

When Scolyer received his glioblastoma diagnosis, the standard of care offered little comfort. The protocol for treating the disease — surgical excision, then radiotherapy and chemotherapy — has changed almost nothing in twenty years. Most patients survive less than twelve months. For a man who had dedicated his life to improving cancer outcomes, passive acceptance was simply not an option.

“It didn’t sit right with me… to just accept certain death without trying something,” he told the BBC in 2024. “It’s an incurable cancer? Well bugger that!”

Professor Long, upon learning of her friend’s diagnosis, spent the first hours in grief — then began to think. Applying the same logic that had proved so effective in melanoma, the two scientists designed a protocol never before attempted in brain cancer: combination immunotherapy administered prior to surgery, supplemented by a personalised cancer vaccine calibrated to the specific molecular characteristics of Scolyer’s tumour. In early 2023, he became the first brain cancer patient in history to receive such treatment. Subsequent imaging appeared to reveal a positive immune response within the brain, and a formal early-stage clinical trial is now underway in the United States.

“This was science in action!” declared Professor John Thompson AO, a close friend and esteemed melanoma surgeon, in a tribute statement. “He will be remembered as a truly great Australian.”

A Final Letter: Grace, Gratitude, and a Call to Action

Throughout his illness, Scolyer documented his treatment publicly and with unflinching honesty, drawing an enormous outpouring of national support. In his final open letter, he acknowledged this with characteristic warmth.

“You’ve laughed with me, cried with me, and provided encouragement and support to keep going just when I needed it most. I haven’t sugar-coated my journey and I sincerely thank you for allowing me the space and opportunity to share it with you, warts and all.”

He described his life as one “filled with happiness, optimism, opportunity and passion,” and expressed profound pride in his family — his wife, fellow pathologist Dr Katie Nicholl, and their three children — calling them “shining examples of the best of humanity.” His closing words carried a message directed outward, toward the scientists and governments who will carry the work forward. “We can and should continue to push boundaries to propel the cancer field forward.”

Conclusion

Richard Scolyer did not survive glioblastoma. But the manner in which he faced it — with scientific creativity, personal courage, radical transparency, and an unflinching commitment to patients he would never meet — ensures that his influence on medicine will endure for decades. The clinical trial now proceeding in the United States is the most tangible expression of that legacy. If its results replicate what was observed in his treatment, the protocol he pioneered could one day transform outcomes for brain cancer patients globally.

He was a doctor who practised what he preached, a scientist who offered his own life as proof of his convictions, and, by any measure, a truly great Australian. Professor Richard Scolyer is survived by his wife Dr Katie Nicholl and their three children. He was 59 years old.